10% 持股人
Broadwood Partners, L.P. is a Delaware limited partnership and pooled investment vehicle managed by Broadwood Capital, Inc., a New York City–based private investment firm formed in 2002 and registered with the U.S. Securities and Exchange Commission.[[1]](https://www.snowballresearch.com/activism/activistprofile/broadwood-partners-l-p/)[[5]](https://www.sec.gov/Archives/edgar/data/1278386/000091957423006645/xslFormDX01/primary_doc.xml)[[8]](https://www.broadwoodcapital.com) Broadwood Partners, L.P. is one of Broadwood Capital’s primary advisory clients and serves sophisticated investors through an actively managed portfolio reviewed on a daily basis, with reporting provided under the terms of its limited partnership agreement.[[1]](https://www.snowballresearch.com/activism/activistprofile/broadwood-partners-l-p/) The partnership is organized in Delaware and maintains its principal business contact through Broadwood Capital, Inc. at offices in New York.[[5]](https://www.sec.gov/Archives/edgar/data/1278386/000091957423006645/xslFormDX01/primary_doc.xml)
Broadwood Partners, L.P. is best known as a significant, long-term shareholder and activist investor in healthcare and medical technology companies, including its role as a more-than 10% owner of STAAR Surgical Company (NASDAQ: STAA).[[2]](https://www.gurufocus.com/insider/23149/broadwood-partners-lp)[[7]](https://www.businesswire.com/news/home/20260106480307/en/Broadwood-Partners-Comments-on-STAAR-Surgical-Shareholders-Rejection-of-the-Companys-Proposed-Sale-to-Alcon) As of recent SEC ownership reports, Broadwood Partners, L.P. and affiliates have held a substantial stake in STAAR Surgical and have publicly engaged with the company’s strategic direction, including commenting on shareholder actions related to a proposed sale of STAAR to Alcon Inc.[[2]](https://www.gurufocus.com/insider/23149/broadwood-partners-lp)[[7]](https://www.businesswire.com/news/home/20260106480307/en/Broadwood-Partners-Comments-on-STAAR-Surgical-Shareholders-Rejection-of-the-Companys-Proposed-Sale-to-Alcon) Beyond STAAR, the partnership has also reported large, often activist positions in issuers such as Lineage Cell Therapeutics and Insight Molecular Diagnostics, reflecting a concentrated, research-driven investment approach under the leadership of Broadwood Capital’s president and principal owner, Neal C. Bradsher.[[1]](https://www.snowballresearch.com/activism/activistprofile/broadwood-partners-l-p/)[[2]](https://www.gurufocus.com/insider/23149/broadwood-partners-lp)[[3]](https://fintel.io/i/broadwood-partners-lp)
查看完整内部人档案 →